GlassScriptPhysician profile
Amy Thompson
NPI 1659915924
$9,353.00
in general payments reported to CMS, 2019-2025
39 companies · $3,997 in 2025
The $3,997 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.96 · 2023: $1,243 · 2024: $4,095 · 2025: $3,997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,767 · Travel and Lodging: $568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,767.25 |
| Travel and Lodging | $567.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,048.32 | 2024 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $772.08 | 2023-2025 | |
| Ucb, INC. | $724.81 | 2023-2025 | Briviact, Rystiggo, Fintepla |
| Lundbeck LLC | $513.22 | 2024-2025 | Vyepti, Rexulti |
| Mallinckrodt Hospital Products INC. | $481.84 | 2023-2025 | Acthar |
| Eisai INC. | $415.34 | 2023-2025 | |
| Biogen, INC. | $412.34 | 2023-2025 | Vumerity, Tysabri, Leqembi |
| Argenx US, INC. | $347.75 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Neurelis, INC. | $347.07 | 2023-2025 | Valtoco |
| Alexion Pharmaceuticals, INC. | $324.13 | 2023-2025 | Ultomiris, Soliris |
| Pfizer INC. | $317.12 | 2023-2025 | |
| Emd Serono, INC. | $301.84 | 2024-2025 | Mavenclad |
| Sk Life Science, INC. | $279.15 | 2023-2025 | |
| Lilly USA, LLC | $260.88 | 2024-2025 | Kisunla, Amyvid |
| E.R. Squibb & Sons, L.L.C. | $244.99 | 2024-2025 | Zeposia |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $209.18 | 2024-2025 | Dysport |
| Tg Therapeutics, INC. | $208.51 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $202.19 | 2024-2025 | Ingrezza |
| Amgen INC. | $194.07 | 2024-2025 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $192.29 | 2023-2025 | Austedo Xr, Austedo Xr |
| Catalyst Pharmaceuticals, INC. | $187.92 | 2023-2025 | Fycompa |
| Jazz Pharmaceuticals INC. | $182.89 | 2023-2025 | |
| Averitas Pharma INC. | $145.85 | 2024-2025 | Qutenza |
| Horizon Therapeutics Plc | $142.88 | 2023 | Uplizna |
| Takeda Pharmaceuticals U.S.A., INC. | $130.58 | 2024-2025 | Hyqvia |
| Scilex Pharmaceuticals INC. | $123.06 | 2023-2025 | Ztlido |
| Otsuka America Pharmaceutical, INC. | $113.69 | 2023-2025 | Rexulti |
| Acadia Pharmaceuticals INC | $102.88 | 2024-2025 | Daybue |
| Axsome Therapeutics, INC. | $76.69 | 2025 | Symbravo |
| Janssen Biotech, INC. | $58.61 | 2025 | |
| Genentech USA, INC. | $55.39 | 2025 | Ocrevus Zunovo |
| Harmony Biosciences LLC | $51.98 | 2023-2024 | Wakix |
| Merz Pharmaceuticals, LLC | $44.52 | 2025 | Xeomin |
| Astrazeneca Pharmaceuticals LP | $33.05 | 2024-2025 | Wainua |
| Ani Pharmaceuticals, INC. | $30.42 | 2024 | Purified Cortrophin Gel |
| Amylyx Pharmaceuticals, INC. | $23.47 | 2023 | Relyvrio |
| Azurity Pharmaceuticals, INC. | $20.46 | 2023 | Eprontia |
| Exeltis, USA INC. | $17.96 | 2022 | |
| Amneal Pharmaceuticals LLC | $13.58 | 2025 | Crexont |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.